Sanofi and Re­gen­eron clear the fin­ish line in an in­flam­ma­to­ry esoph­a­gus dis­ease, leav­ing Take­da in the dust

With atopic der­mati­tis ri­vals breath­ing down Dupix­ent’s neck, Sanofi and Re­gen­eron on Fri­day se­cured a first win in new ter­ri­to­ry in what Sanofi’s head of im­munol­o­gy and in­flam­ma­tion Naimish Pa­tel called the fastest ap­proval he’s ever seen.

The FDA ap­proved Dupix­ent on Fri­day to treat pa­tients 12 years and old­er with eosinophilic esophagi­tis (EoE), an in­flam­ma­to­ry con­di­tion that caus­es swelling and scar­ring of the esoph­a­gus. The ap­proval came just a cou­ple months af­ter reg­u­la­tors grant­ed Dupix­ent pri­or­i­ty re­view, and months ahead of its PDU­FA date on Aug. 3.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.